Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Leonidas N Carayannopoulos"'
Autor:
Corinne Carland, Lei Zhao, Oday Salman, Jordana B. Cohen, Payman Zamani, Qing Xiao, Ashok Dongre, Zhaoqing Wang, Christina Ebert, Danielle Greenawalt, Vanessa van Empel, A. Mark Richards, Robert N. Doughty, Ernst Rietzschel, Ali Javaheri, Yixin Wang, Peter H. Schafer, Sarah Hersey, Leonidas N. Carayannopoulos, Dietmar Seiffert, Ching‐Pin Chang, David A. Gordon, Francisco Ramirez‐Valle, Douglas L. Mann, Thomas P. Cappola, Julio A. Chirinos
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 9 (2024)
Background Although several studies have addressed plasma proteomics in heart failure with preserved ejection fraction, limited data are available on the prognostic value of urinary proteomics. The objective of our study was to identify urinary prote
Externí odkaz:
https://doaj.org/article/31d03371ea994940952d131d3a850e78
Autor:
Ying, Ye, Allison, Gaudy, Michael, Thomas, Josephine, Reyes, Barbara, Burkhardt, Gerald, Horan, Liangang, Liu, Jian, Chen, Atalanta, Ghosh, Leonidas N, Carayannopoulos, Daniel A, Tatosian, Maria, Palmisano
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1394-1404
CC-90001 selectively inhibits c-Jun N-terminal kinase (JNK), a stress-activated protein implicated in fibrosis. In 3 phase 1 trials evaluating CC-90001 pharmacokinetics, pharmacodynamics, and safety, healthy adults (N = 184) received oral CC-90001 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e76922352cef31abbd395278d3c483
https://doi.org/10.1002/cpdd.1178
https://doi.org/10.1002/cpdd.1178
Autor:
Slim Fourati, Razvan Cristescu, Andrey Loboda, Aarthi Talla, Ali Filali, Radha Railkar, Andrea K. Schaeffer, David Favre, Dominic Gagnon, Yoav Peretz, I-Ming Wang, Chan R. Beals, Danilo R. Casimiro, Leonidas N. Carayannopoulos, Rafick-Pierre Sékaly
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-12 (2016)
Ageing is associated with poor responses to vaccines but the underlying mechanism remains unclear. Here the authors use a systems-based approach to define molecular signatures present before vaccination that correlate with non-responsiveness to hepat
Externí odkaz:
https://doaj.org/article/3d312c5aa0404caa898a6b2a5c38fdde
Autor:
Michael Thomas, Maria Palmisano, Mark Thomas, Sekhar Surapaneni, Yongjun Xue, Mary Liu, Simon Zhou, Rebecca N. Wood-Horrall, Gopal Krishna, Liangang Liu, Leonidas N Carayannopoulos, Ken Ogasawara
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:941-952
Fedratinib, an oral, selective Janus kinase 2 inhibitor, has been shown to inhibit P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT) 2, and mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d770833137270f254670e8ca5601cb8
https://doi.org/10.1007/s00280-021-04346-7
https://doi.org/10.1007/s00280-021-04346-7
Autor:
Yongjun Xue, Sekhar Surapaneni, Mark Thomas, Gopal Krishna, Leonidas N Carayannopoulos, Simon Zhou, Mary Liu, Jeanelle Kam, Liangang Liu, Ken Ogasawara, Maria Palmisano
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:369-377
Fedratinib is an oral and selective Janus kinase 2 inhibitor that is indicated for treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis. Fedratinib is metabolized by cytochrome P450s (CYPs), primarily CYP3A4. The ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417c826164b7422aa497fea66d144d4b
https://doi.org/10.1007/s00280-021-04292-4
https://doi.org/10.1007/s00280-021-04292-4
Autor:
Yizhe Chen, Ken Ogasawara, Rebecca Wood-Horrall, Mark Thomas, Michael Thomas, Bing He, Liangang Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N. Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna
Publikováno v:
Cancer chemotherapy and pharmacology. 90(4)
Purpose Fedratinib is an orally administered Janus kinase (JAK) 2–selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. In vitro, fedratinib is predominantly metabolized by cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ab1303424f2538574182d7f8ba74c2
https://pubmed.ncbi.nlm.nih.gov/36001108
https://pubmed.ncbi.nlm.nih.gov/36001108
Autor:
Eric Lazear, Michel M. Sun, Xiaoli Wang, Theresa L. Geurs, Christopher A. Nelson, Jessica A. Campbell, Danna Lippold, Alexander S. Krupnick, Randall S. Davis, Leonidas N. Carayannopoulos, Anthony R. French, Daved H. Fremont
NKG2D is a key component of cytotoxic antitumor and antiviral responses. Multiple viruses evade NKG2D recognition by blocking NKG2D ligand expression on infected cells. In contrast, cowpox virus targets NKG2D directly by encoding a secreted antagonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e42e5cc5cd2a1d69bd95f2a9190ac02b
Publikováno v:
Clinical Pharmacology: Advances and Applications. 8:117-125
Yan Li,Leonidas N Carayannopoulos,Michael Thomas,Maria Palmisano,Simon Zhou Translational Development and Clinical Pharmacology, Celgene Corporation, Summit, NJ, USA Abstract: CC-122 hydrochloride is a novel pleiotropic pathway modifier compound that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb0a456a0424bbc33a4c3ba7e40ba9f
https://doi.org/10.2147/cpaa.s111867
https://doi.org/10.2147/cpaa.s111867
Autor:
Leonidas N. Carayannopoulos, Theresa L. Geurs, Anthony R. French, Leslie A. Fogel, Michel M. Sun
Publikováno v:
The Journal of Immunology. 190:6269-6276
NK cell activation is controlled by the integration of signals from cytokine receptors and germline–encoded activation and inhibitory receptors. NK cells undergo two distinct phases of activation during murine CMV (MCMV) infection: a nonselective p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb03df69b8e6484f552818a088d837bc
https://doi.org/10.4049/jimmunol.1202533
https://doi.org/10.4049/jimmunol.1202533
Publikováno v:
Clinical Pharmacology : Advances and Applications
CC-122 hydrochloride is a novel pleiotropic pathway modifier compound that binds cereblon, a substrate receptor of the Cullin 4 RING E3 ubiquitin ligase complex. CC-122 has multiple activities including modulation of immune cells, antiproliferative a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fac457e2aa4210428847f37655846625
https://pubmed.ncbi.nlm.nih.gov/27672344
https://pubmed.ncbi.nlm.nih.gov/27672344